BACKGROUND: There is anecdotal evidence that nebulised saline relieves breathlessness at rest in patients with severe chronic obstructive pulmonary disease (COPD). It is unclear whether nebulised beta agonists are any more effective than nebulised saline in relieving breathlessness at rest in these individuals. AIM: To compare the effects of nebulised saline and nebulised terbutaline on breathlessness at rest in patients with severe COPD. METHODS: We studied 18 patients with severe COPD with a mean age of 71.1 years, forced expiratory volume in 1 second (FEV1) of 0.58 L and vital capacity (VC) of 1.59 L, in a randomised, double-blind, crossover trial. The subjects received three doses of nebulised saline on one study day, and three doses of nebulised terbutaline (cumulative dose 10 mg) on the other. Breathlessness was measured using Likert and Visual Analogue Scales (VAS). RESULTS: Both treatments led to a significant improvement in breathlessness on VAS and Likert scales but there was no significant difference in breathlessness scores for saline compared with terbutaline. There was a small but significant increase in FEV1 with terbutaline of 74 mL, but no change with saline. CONCLUSIONS: A saline aerosol has no effect on lung function but reduces breathlessness at rest in subjects with severe COPD. Nebulised saline may be considered as an adjunct to the use of nebulised bronchodilators for the treatment of breathlessness in patients with COPD.
RCT Entities:
BACKGROUND: There is anecdotal evidence that nebulised saline relieves breathlessness at rest in patients with severe chronic obstructive pulmonary disease (COPD). It is unclear whether nebulised beta agonists are any more effective than nebulised saline in relieving breathlessness at rest in these individuals. AIM: To compare the effects of nebulised saline and nebulised terbutaline on breathlessness at rest in patients with severe COPD. METHODS: We studied 18 patients with severe COPD with a mean age of 71.1 years, forced expiratory volume in 1 second (FEV1) of 0.58 L and vital capacity (VC) of 1.59 L, in a randomised, double-blind, crossover trial. The subjects received three doses of nebulised saline on one study day, and three doses of nebulised terbutaline (cumulative dose 10 mg) on the other. Breathlessness was measured using Likert and Visual Analogue Scales (VAS). RESULTS: Both treatments led to a significant improvement in breathlessness on VAS and Likert scales but there was no significant difference in breathlessness scores for saline compared with terbutaline. There was a small but significant increase in FEV1 with terbutaline of 74 mL, but no change with saline. CONCLUSIONS: A saline aerosol has no effect on lung function but reduces breathlessness at rest in subjects with severe COPD. Nebulised saline may be considered as an adjunct to the use of nebulised bronchodilators for the treatment of breathlessness in patients with COPD.
Authors: Capucine Morélot-Panzini; Carl R O'Donnell; Robert W Lansing; Richard M Schwartzstein; Robert B Banzett Journal: Respir Physiol Neurobiol Date: 2017-10-12 Impact factor: 1.931
Authors: Robert W Hallowell; Richard Schwartzstein; Carl R O'Donnell; Andrew Sheridan; Robert B Banzett Journal: Lung Date: 2019-11-15 Impact factor: 2.584
Authors: Martin Koppitz; Charlotte Eschenburg; Emilia Salzmann; Martin Rosewich; Ralf Schubert; Stefan Zielen Journal: PLoS One Date: 2016-06-16 Impact factor: 3.240
Authors: P Barski; M Surdacki; A Saj; A Wróblewska; M Ornat; A Pawelak; D Pompa; J Jurgiel; V Ermisch; A Hirnle; I Pirogowicz; I Stanisławska; M Łyp; M Pokorski Journal: Physiol Res Date: 2020-03-27 Impact factor: 1.881